The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies
Preprint
Abstract
There is an ongoing global effort to design, manufacture, and clinically assess vaccines against SARS-CoV-2. Over the course of the ongoing pandemic a number of new SARS-CoV-2 virus isolates or variants of concern (VoC) have been identified containing mutations in key proteins. In this study we describe the generation and preclinical assessment of a ChAdOx1-vectored vaccine (AZD2816) which expresses the spike protein of the Beta VoC (B.1.351). We demonstrate that AZD2816 is immunogenic after a single dose. When AZD2816 is used as a booster dose in animals primed with a vaccine encoding the original spike protein (ChAdOx1 nCoV-19/ [AZD1222]), high titre binding and neutralising antibodies against Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) are induced. In addition, a strong and polyfunctional T cell response was measured in these booster regimens. These data support the ongoing clinical development and testing of this new variant vaccine.Keywords
All Related Versions
- Published version: EBioMedicine, 77, 103902.
This publication has 33 references indexed in Scilit:
- Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody RecognitionCell Host & Microbe, 2021
- SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivoScience, 2020
- Structure-based design of prefusion-stabilized SARS-CoV-2 spikesScience, 2020
- The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and AntigenicityCell, 2020
- Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaquesNature, 2020
- Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19npj Vaccines, 2020
- COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19Antibody Therapeutics, 2020
- Potently neutralizing and protective human antibodies against SARS-CoV-2Nature, 2020
- Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in miceNature Communications, 2020
- A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative ImmunogenicityPLOS ONE, 2012